Shares of Metsera, Inc. (NASDAQ:MTSR – Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $29.16, but opened at $28.00. Metsera shares last traded at $28.04, with a volume of 95,958 shares.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the company. Bank of America initiated coverage on Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price target on the stock. Guggenheim assumed coverage on shares of Metsera in a report on Tuesday, February 25th. They set a “buy” rating and a $56.00 price objective on the stock. Evercore ISI started coverage on Metsera in a research report on Tuesday, February 25th. They set an “outperform” rating for the company. Finally, Cantor Fitzgerald started coverage on Metsera in a research report on Tuesday, February 25th. They issued an “overweight” rating on the stock.
Read Our Latest Report on Metsera
Metsera Stock Up 6.8 %
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Stories
- Five stocks we like better than Metsera
- Most active stocks: Dollar volume vs share volume
- Archer Aviation Stock Sees Surge in Institutional Buys
- Canada Bond Market Holiday: How to Invest and Trade
- These 4 Stocks Offer High Upside in the AI Data Center Boom
- What is a Secondary Public Offering? What Investors Need to Know
- How Can Tomahawk 6 Contribute to Broadcom’s AI Growth Story?
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
